SpinaFX Advances Breakthrough Spine Therapy With ASSR 2026 Workshop and Pivotal Trial Plans

SpinaFX Medical Inc featured prominently at the American Society of Spine Radiology (ASSR) 2026 meeting in New Orleans, underscoring its focus on minimally invasive, image-guided spine therapy for contained herniated discs. The company highlighted its intra-discal oxygen ozone injection approach, which has received FDA Breakthrough Device designation.

Senior leaders, including the chief medical, strategy, and clinical affairs officers, attended the meeting to engage directly with spine radiologists and interventional specialists. Their presence aimed to build clinical credibility, deepen relationships with key opinion leaders, and position the therapy for future adoption.

A hands-on workshop on February 25, led by an external physician, drew strong interest and provided practical training in C-arm guided needle placement. Participants also reviewed clinical evidence, patient selection criteria, and follow-up protocols related to the procedure.

During the workshop, SpinaFX outlined plans for a pivotal clinical trial designed to generate more robust data on safety and effectiveness. This planned study marks a transition toward a more advanced clinical development phase, which could be important for eventual regulatory review and reimbursement discussions.

The combination of specialty conference visibility, clinician education, and trial planning suggests SpinaFX is laying groundwork for broader market entry in spine-focused medtech. While no specific regulatory or commercial milestones were announced, the week’s activities indicate steady progress toward potential commercialization of its breakthrough-designated spine therapy.